NAGE vs. AMRX
NAGE (Niagen Bioscience, Inc) and AMRX (Amneal Pharmaceuticals, Inc.) are both stocks. Both are in the Healthcare sector — NAGE in Biotechnology, AMRX in Drug Manufacturers - Specialty & Generic. Over the past 10 years, NAGE returned -1.18%/yr vs -5.11%/yr for AMRX. Their 0.11 correlation means their historical movements had little consistent relationship.
Performance
NAGE vs. AMRX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NAGE achieves a -46.54% return, which is significantly lower than AMRX's 45.40% return. Over the past 10 years, NAGE has outperformed AMRX with an annualized return of -1.18%, while AMRX has yielded a comparatively lower -5.11% annualized return.
NAGE
- 1D
- 2.41%
- 1M
- -0.87%
- 6M
- -43.24%
- YTD
- -46.54%
- 1Y
- -62.39%
- 3Y*
- 25.75%
- 5Y*
- -17.11%
- 10Y*
- -1.18%
- ALL TIME*
- -5.25%
AMRX
- 1D
- -0.97%
- 1M
- 6.82%
- 6M
- 33.92%
- YTD
- 45.40%
- 1Y
- 133.97%
- 3Y*
- 79.45%
- 5Y*
- 30.02%
- 10Y*
- -5.11%
- ALL TIME*
- 11.78%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $32.37M | $32.67M | $30.54M | |
| $2.07M | $2.33M | $3.13M |
NAGE vs. AMRX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NAGE Niagen Bioscience, Inc | -46.54% | 19.89% | 270.98% | -14.88% | -55.08% | -22.08% | 11.37% | 25.66% | -41.67% | 77.64% |
AMRX Amneal Pharmaceuticals, Inc. | 45.40% | 59.09% | 30.48% | 205.03% | -58.46% | 4.81% | -5.19% | -64.38% | -18.74% | 25.66% |
Correlation
The correlation between NAGE and AMRX is 0.22, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.22 |
Correlation (3Y) Balances recent behavior with more history. | 0.19 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.23 |
Correlation (10Y) Provides a long-term view across more market conditions. | 0.18 |
Correlation (All Time) Calculated using the full available price history since Jan 15, 2009 | 0.11 |
The correlation between NAGE and AMRX shifts across timeframes, from 0.11 (all time) to 0.23 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
NAGE:
$270.79M
AMRX:
$5.85B
NAGE:
$0.22
AMRX:
$0.48
NAGE:
15.55
AMRX:
37.97
NAGE:
0.13
AMRX:
1.32
NAGE:
2.22
AMRX:
1.92
NAGE:
3.49
AMRX:
182.01
NAGE:
$130.42M
AMRX:
$3.12B
NAGE:
$83.83M
AMRX:
$1.23B
NAGE:
$13.37M
AMRX:
$447.79M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NAGE vs. AMRX — Risk / Return Rank
NAGE
AMRX
NAGE vs. AMRX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Niagen Bioscience, Inc (NAGE) and Amneal Pharmaceuticals, Inc. (AMRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NAGE | AMRX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -5.38 | ||
| Sortino ratioReturn per unit of downside risk | -6.88 | ||
| Omega ratioGain probability vs. loss probability | 0.74 | 1.58 | -0.84 |
| Calmar ratioReturn relative to maximum drawdown | -0.93 | 6.07 | -7.00 |
| Martin ratioReturn relative to average drawdown | -1.38 | 15.13 | -16.51 |
Loading charts...
Drawdowns
NAGE vs. AMRX - Drawdown Comparison
The maximum NAGE drawdown since its inception was -97.00%, roughly equal to the maximum AMRX drawdown of -97.52%. Use the drawdown chart below to compare losses from any high point for NAGE and AMRX.
Loading charts...
Drawdown Indicators
| NAGE | AMRX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.00% | -97.52% | +0.52% |
Max Drawdown (1Y)Largest decline over 1 year | -68.91% | -22.25% | -46.66% |
Max Drawdown (3Y)Largest decline over 3 years | -77.86% | -26.80% | -51.06% |
Max Drawdown (5Y)Largest decline over 5 years | -86.58% | -78.29% | -8.29% |
Max Drawdown (10Y)Largest decline over 10 years | -93.65% | -95.87% | +2.22% |
Current DrawdownCurrent decline from peak | -81.86% | -64.30% | -17.56% |
Average DrawdownAverage peak-to-trough decline | -75.76% | -54.42% | -21.34% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 46.13% | 8.91% | +37.22% |
Volatility
NAGE vs. AMRX - Volatility Comparison
Niagen Bioscience, Inc (NAGE) has a higher volatility of 14.85% compared to Amneal Pharmaceuticals, Inc. (AMRX) at 9.86%. This indicates that NAGE's price experiences larger fluctuations and is considered to be riskier than AMRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NAGE | AMRX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 14.85% | 9.86% | +4.99% |
Volatility (6M)Calculated over the trailing 6-month period | 36.77% | 25.71% | +11.06% |
Volatility (1Y)Calculated over the trailing 1-year period | 49.10% | 33.29% | +15.81% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 76.59% | 50.81% | +25.78% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 78.49% | 65.25% | +13.24% |
Dividends
NAGE vs. AMRX - Dividend Comparison
Neither NAGE nor AMRX has paid dividends to shareholders.
Financials
NAGE vs. AMRX - Financials Comparison
This section allows you to compare key financial metrics between Niagen Bioscience, Inc and Amneal Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NAGE vs. AMRX - Profitability Comparison
NAGE - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Niagen Bioscience, Inc reported a gross profit of 19.98M and revenue of 31.47M. Therefore, the gross margin over that period was 63.5%.
AMRX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Amneal Pharmaceuticals, Inc. reported a gross profit of 334.51M and revenue of 796.20M. Therefore, the gross margin over that period was 42.0%.
NAGE - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Niagen Bioscience, Inc reported an operating income of 1.58M and revenue of 31.47M, resulting in an operating margin of 5.0%.
AMRX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Amneal Pharmaceuticals, Inc. reported an operating income of -1.30M and revenue of 796.20M, resulting in an operating margin of -0.2%.
NAGE - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Niagen Bioscience, Inc reported a net income of 6.32M and revenue of 31.47M, resulting in a net margin of 20.1%.
AMRX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Amneal Pharmaceuticals, Inc. reported a net income of 57.66M and revenue of 796.20M, resulting in a net margin of 7.2%.
Frequently Asked Questions
NAGE and AMRX have a correlation of 0.22, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NAGE has higher volatility (14.85%) compared to AMRX (9.86%). In terms of maximum drawdown, NAGE dropped -97.00% vs AMRX's -97.52%.
AMRX currently has the higher Sharpe Ratio (4.08 vs -1.30), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NAGE and AMRX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer